- Home
- BCSF vs YDES Comparison
BCSF vs YDES Comparison
Compare BCSF & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BCSF | YDES |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.5M | 894.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCSF | YDES |
|---|---|---|
| Price | $13.64 | $11.97 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 391.6K | 62.4K |
| Earning Date | 02-26-2026 | 09-30-2025 |
| Dividend Yield | ★ 13.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $278,347,000.00 | $510,360.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.48 | ★ N/A |
| Revenue Growth | N/A | ★ 45.76 |
| 52 Week Low | $13.20 | $5.30 |
| 52 Week High | $19.21 | $31.00 |
Technical Indicators
Market Signals| Indicator | BCSF | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | N/A |
| Support Level | $13.46 | N/A |
| Resistance Level | $13.87 | N/A |
| Average True Range (ATR) | 0.28 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 20.22 | 0.00 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.